The EPS projection of Acorda Therapeutics, Inc. (NASDAQ:ACOR) for quarter ended 2016-09-30 is $-0.09. A week before, the EPS forecast was $-0.09 against target of $-0.09, a month earlier. This estimate stood at $-0.09 60 days earlier versus forecast of $-0.09 90 days earlier, confirming a deviation of 0%.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 1, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Acorda Therapeutics, Inc. (NASDAQ:ACOR) in the preceding 120, 60, 30 and 90 days were 0, 0, 0 and 0, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Acorda Therapeutics, Inc. (NASDAQ:ACOR) was $-0.09. This projection was computed after accounting 2 calls. As reported on 2016-04-28 the EPS was $0.01. The change was $0.03, demonstrating a percentage deviation of 150%. The projections confirmed a standard deviation of 0.1.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Acorda Therapeutics, Inc. (NASDAQ:ACOR) stands at $143.136 and the median estimate at $143.6. Almost 3 analysts announced their estimates.
The highest estimate is $144.5 while the lowest target is $141.31 showing standard deviation of 1.644%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of -0.946%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Acorda Therapeutics, Inc. (NASDAQ:ACOR) stated that the change in forecast was -1.258%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...